Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. (Q51963509)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 June 2008

Language	Label	Description	Also known as
English	Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses.	scientific article published on 17 June 2008

Statements

scholarly article

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. (English)

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

William C. Gruber

6

object named as

William C Gruber

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

author name string

Sigurveig Th Sigurdardottir

1

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

Katrin Davidsdottir

2

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

Vilhjalmur A Arason

3

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

Olof Jonsdottir

4

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

France Laudat

5

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

Ingileif Jonsdottir

7

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

language of work or name

0 references

publication date

17 June 2008

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

26

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

33

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

4178-4186

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Impact of meningococcal C conjugate vaccine in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Meningococcal surrogates of protection--serum bactericidal antibody activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Control of pneumococcal disease in the United Kingdom--the start of a new era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.05.072

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/18606481

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51963509&oldid=1775335997"